Azitra is trading at $0.14, up 7.63%, with no company-specific catalyst identified for the October 2 move. - On October 1, Azitra announced that its ATR04-484 Phase 1/2 trial can advance to Cohort 2 after a safety review; available reporting does not connect the news to the gain. - The move is in the same direction as broader markets, with the S&P 500 up 0.86% and the Nasdaq Composite up 1.41%.